STUDY SEARCH RESULTS

2 studies found for your search request:  3475-991

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (...
Condition: Metastatic Hormone-Sensitive Prostate Cancer
Minimum Age: 18 years, Maximum Age: N/A
Gender: Male
Study ID: NCT04191096
Status: Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (...
Condition: Metastatic Hormone-Sensitive Prostate Cancer
Minimum Age: 18 years, Maximum Age: N/A
Gender: Male
Study ID: NCT04934722
Status: Completed




Copyright © 2026 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  Consumer Health Data Privacy Policy  Your Privacy Choices   Accessibility  U.S. Corporate Site